Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Embla Medical hfOCSE:EMBLA -1.17%91 Cyclically Adjusted PS Ratio is 2.02 as of Aug. 13, 2026, which is 51% below its 10-year median of 4.14. GuruFocus rates OCSE:EMBLA with a GF Score™ of 91/100 and a GF Value™ of kr34.11 (Modestly Undervalued). Among 526 Medical Devices & Instruments companies, Embla Medical hf ranks better than 53.8% on this metric.
The historical rank and industry rank for Embla Medical hf's Cyclically Adjusted PS Ratio or its related term are showing as below:
OCSE:EMBLA'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.8 Med: 4.14 Max: 7.2
Current: 2.05
During the past years, Embla Medical hf's highest Cyclically Adjusted PS Ratio was 7.20. The lowest was 1.80. And the median was 4.14.
OCSE:EMBLA's Cyclically Adjusted PS Ratio is ranked better than 53.8% of 526
companies
in the Medical Devices & Instruments industry
Industry Median: 2.305
vs OCSE:EMBLA: 2.05
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Embla Medical hf's adjusted revenue per share data for the three months ended in Jun. 2026 was kr3.905. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is kr14.61 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Embla Medical hf (OCSE:EMBLA) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Embla Medical hf Cyclically Adjusted PS Ratio Related Terms
Embla Medical hf Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Embla Medical hf's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Embla Medical hf Cyclically Adjusted PS Ratio Chart
OCSE:EMBLA vs ABT, SYK, MDT: Cyclically Adjusted PS Ratio Comparison
For the Medical Devices subindustry, Embla Medical hf's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Embla Medical hf Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Embla Medical hf's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Embla Medical hf's Cyclically Adjusted PS Ratio falls into.
Embla Medical hf Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Embla Medical hf's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 2.02 mean?
Embla Medical hf (OCSE:EMBLA) has a Cyclically Adjusted PS Ratio of 2.02 as of Aug. 13, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Embla Medical hf and its competitors. This is 51% below median its historical median of 4.14. Over the past decade, Embla Medical hf's Cyclically Adjusted PS Ratio has ranged from 1.80 to 7.20. According to the industry distribution chart, Embla Medical hf ranks #243 out of 526 companies in the Medical Devices & Instruments industry, placing it in the top 46.2%.
Is Embla Medical hf's Cyclically Adjusted PS Ratio too high?
Embla Medical hf's current Cyclically Adjusted PS Ratio of 2.02 is 51% below median its 10-year median of 4.14. Over the past 10 years, this metric has ranged from a low of 1.80 to a high of 7.20. The Medical Devices & Instruments industry median Cyclically Adjusted PS Ratio is 2.31. Embla Medical hf's value of 2.02 is 12.4% below this industry median. Based on the distribution chart, Embla Medical hf ranks #243 out of 526 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Embla Medical hf has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Embla Medical hf's Cyclically Adjusted PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Embla Medical hf ranks #243 out of 526 companies for Cyclically Adjusted PS Ratio. This puts Embla Medical hf in the upper half of its industry. The industry median Cyclically Adjusted PS Ratio is 2.31. Embla Medical hf's value of 2.02 is 12.4% below this benchmark. Historically, Embla Medical hf's own Cyclically Adjusted PS Ratio has ranged from 1.80 to 7.20 over the past decade. While the company's 10-year median is 4.14 vs. the industry median of 2.31, Embla Medical hf has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PS Ratio among Medical Devices & Instruments companies is 2.31, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Embla Medical hf's current Cyclically Adjusted PS Ratio of 2.02 is 12.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Embla Medical hf and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PS Ratio is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Embla Medical hf's current Cyclically Adjusted PS Ratio is 2.02, which is 51% below median its own 10-year median of 4.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embla Medical hf stock overvalued right now?
Based on GuruFocus' analysis, Embla Medical hf (OCSE:EMBLA) is currently considered Modestly Undervalued. The stock's GF Value™ is kr34.11, compared to a current price of kr29.55 — trading 13.4% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 2.02, which is 51% below median its 10-year median of 4.14 and 12.4% below the Medical Devices & Instruments industry median of 2.31. Embla Medical hf's overall GF Score™ is 91/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Embla Medical hf (OCSE:EMBLA), the current Cyclically Adjusted PS Ratio is 2.02 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Embla Medical hf (OCSE:EMBLA) Overvalued in 2026?
Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued.
The current stock price of kr29.55 is trading 13.4% below its estimated GF Value™ of kr34.11.
GuruFocus considers Embla Medical hf to be Modestly Undervalued.
Key valuation signals for OCSE:EMBLA:
Cyclically Adjusted PS Ratio: 2.02 (51% below median its 10-year median of 4.14)
GF Value™: kr34.11 vs. price of kr29.55 (13.4% below fair value)
Industry Position: 12.4% below the Medical Devices & Instruments median (#243 of 526)
No single metric tells the full story. See the OCSE:EMBLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
91GF Score
Get the complete analysis for OCSE:EMBLA
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:EMBLA has been successfully added to your 
